Agilent 280-DS Mechanical Qualification System
The Agilent 280-DS Mechanical Qualification System (MQS) simplifies dissolution qualification. The system that has taken the dissolution industry by storm now has even more capabilities.
AGILENT 280-DS MQS CAPABILITIES EXTENDED
The Agilent 280-DS Mechanical Qualification System (MQS) redefines dissolution qualification. By making the physical parameter measurement simple and reliable, instrument integrity is vastly improved and failure investigations as a result of qualification failure are limited, if not entirely avoided. The accompanying software guides the user step-by-step through the qualification process and even trends instrument data to reveal potential problems before they become out-of-tolerance.
New! Compatible since its initial 2012 release with all Agilent, Varian, and VanKel models (as well as most open-head designed systems from various manufacturers), the 280-DS is now even more flexible. Minor modifications to the Vessel Module-including add-on spacers and an arm extension-have expanded the range of vessel heights where the 280-DS can be utilized.
All units currently being shipped contain these improvements, and existing units may be easily upgraded at the time of recalibration.
For more information on the 280-DS MQS, please contact your Agilent Representative, or email us at: dissolution.hotline@agilent.com.
Contact Details:
Company name: Agilent Technologies Inc. Website: www.agilent.com/lifesciences/280-DS
E-mail: dissolution.hotline@agilent.com.
Company Address
Agilent Technologies, Inc.
5301 Stevens Creek Blvd.
Santa Clara, CA 95051
United States
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
